Nuvation Bio shares are surging today after RBC analysts flagged a potential $3 billion opportunity tied to the company’s brain cancer drug. The bullish call has put the spotlight on the biotech’s lead therapy and its path toward treating hard-to-address brain tumors. Investors are reacting quickly to the note, pushing the stock higher in early trading. Analyst endorsements like this can shift sentiment fast, especially for smaller drugmakers with a single high-profile asset.